AstraZeneca: priority treatment for bladder cancer

(CercleFinance.com) - AstraZeneca announced on Friday that the US FDA had granted priority review to its Imfinzi immunotherapy for the treatment of patients with muscle-invasive bladder cancer.


The biopharmaceutical group said it was basing its application on preliminary results from a Phase III clinical trial showing that Imfinzi reduced the risk of disease progression, recurrence, no need for surgery or death in participants by 32% compared to chemotherapy.

At the end of two years, 67.8% of treated patients had not experienced such events, compared with 59.8% in the comparison group.

The FDA grants priority review to drug applications when it deems they have the potential to significantly improve the diagnosis, treatment or prevention of serious diseases.

The US health agency has scheduled its decision for the second quarter of 2025.


Copyright (c) 2024 CercleFinance.com. All rights reserved.